China's medical insurance catalog includes 51 innovative drugs, including first domestic IL-23p19 antibody
The 2026 national basic medical insurance, maternity insurance, and work injury insurance drug catalog was released on November 14. The catalog includes 107 drugs, with 51 being category 1 innovative drugs. The average time from drug approval to medical insurance inclusion has shortened from 5 years to about 1 year, with 80% of innovative drugs entering payment within two years of launch.
The 2026 national medical insurance drug catalog
The catalog includes 51 category 1 innovative drugs, with several approved and included in the same year. Demogic monoclonal antibody, a long-acting biological agent, was approved and included in the national medical insurance catalog in the first half of the year. Demogic monoclonal antibody is the first and only approved long-acting biological agent for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, requiring injections only twice a year.
Ecorit monoclonal antibody, the first bispecific antibody included in medical insurance for follicular lymphoma, was approved in China in May 2026, commercially launched in October, and included in the national medical insurance catalog in November. The medical insurance catalog adjustment process added a pre-application mechanism for innovative drugs that have completed technical review but have not yet received formal marketing approval.
The pre-application mechanism
This pre-application allows drugs to be submitted before approval, preventing a one-year wait and shortening the time from market launch to medical insurance inclusion. Professor Zhang Luo, director of the Department of ENT at the Chinese Physicians Association, stated that traditional treatments still face challenges like recurrence and insufficient long-term control for patients with type 2 inflammation.
Professor Chen Rongchang, director of the Shenzhen Respiratory Disease Institute, noted that some COPD patients with eosinophilic phenotypes may face recurrent acute exacerbations and hospitalization risks even with standard treatment. Professor Ma Jun, director of the Harbin Hematology and Oncology Institute, stated that the relapse-retreatment-relapse cycle in oncology requires more mechanism-based innovations and evidence-based treatment options.
The Chinese clinical oncology society
The Chinese Clinical Oncology Society monitors the early diagnosis of follicular lymphoma patients, many of whom are still working and have family responsibilities. The 2026 national medical insurance drug catalog includes 107 drugs, with 51 being category 1 innovative drugs.
Glossary
- severe eosinophilic asthma — severe eosinophilic asthma is a condition for which Demogic monoclonal antibody is the first and only approved long-acting biological agent. This drug requires injections only twice a year.
- chronic rhinosinusitis with nasal polyps — chronic rhinosinusitis with nasal polyps is a condition for which Demogic monoclonal antibody is the first and only approved long-acting biological agent. This drug requires injections only twice a year.
- bispecific antibody — Ecorit monoclonal antibody is the first bispecific antibody included in medical insurance for follicular lymphoma. This drug was approved in China in May 2026, commercially launched in October, and included in the national medical insurance catalog in November.
- follicular lymphoma — The Chinese Clinical Oncology Society monitors the early diagnosis of follicular lymphoma patients. The 2026 national medical insurance drug catalog includes 107 drugs, with 51 being category 1 innovative drugs.
This article was written with AI assistance from multiple news reports and is reviewed by our editors under our editorial principles. Editorial Standards · Tips & Contact
Comments 0